Cas:29520-14-7 N-Carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide hydrochloride manufacturer & supplier

Chemical Name:N-Carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide hydrochloride

CAS.NO:29520-14-7

Synonyms:guanfacine hydrochloride salt;guanfacine hcl

Molecular Formula:C₉H₁₀Cl₃N₃O

Molecular Weight:282.55400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:78.97000

Exact Mass:280.98900

LogP:3.53850

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like guanfacine hydrochloride salt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,guanfacine hcl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,guanfacine hcl Use and application,guanfacine hydrochloride salt technical grade,usp/ep/jp grade.

Related News: In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. N-Carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide hydrochloride manufacturer An effective treatment for Alzheimer��s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally. N-Carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide hydrochloride supplier If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such. N-Carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide hydrochloride vendor In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn. N-Carbamimidoyl-2-(2,6-dichlorophenyl)-acetamide hydrochloride factory In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.